chief executive officer
Zubin oversaw the delivery of over 1 Billion in IT projects in Afghanistan, Iraq, Africa and Myanmar including USAID, FEMA, SOCOM, British SF and NATO SF DND Canada. Zubin has spent many years delivering satellite communications for numerous Aid agencies and NGO’s. Currently, Zubin is building an AI based medical supply delivery drone program as part of his aid initiative for remote, resource scarce communities to safely deliver COVD-19 therapeutics.
Chief Technical Officer
Chris is the CTO of Skymount Medical Group. He combines invention and social ethics with technical analytical thinking, communication, and teamwork. Chris is the former Executive Officer of Space and Naval Warfare Systems and has 20 years of experience in architecting complex enterprise systems including the NATO ITM enterprise cloud and the United States Navy’s first Enterprise Data Center within the Navy Marine Corps Intranet (NMCI). He is a Veteran of the United States Navy and has served through Operation Enduring Freedom, Operation Iraqi Freedom, and Operation Unified Assistance where he was awarded the Humanitarian Medal for his works in Indonesia and Sri Lanka.
Dr. Bruce Forrest
MB, BS, MD, MBA, Chief Medical Officer
A pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs for over 30 years. Prior to joining the pharmaceutical industry, was a Clinical Research Fellow at the London School of Hygiene and Tropical Medicine and subsequently the MRC AIDS Vaccine Clinical Trials Coordinator at Public Health England. Joined United Biomedical, Inc. in 1993 leading the earliest clinical development of HIV vaccines, initiating clinical trials in China, Australia, Brazil, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). At Wyeth led the clinical activities supporting the market authorization for RotaShield® (EU), Prevnar® (Global), and FluMist®. As Vice President, Regional Research; Executive Director, Research and Development (Corporate Officer), and, Member of the Board of Wyeth K.K. (a joint venture with Takeda Pharmaceuticals), was responsible for all Japan and Asia-Pacific pharmaceutical Research and Development leading a full service Japan-based R&D organization including finance, outsourcing, compliance, clinical research, clinical operations, project management, regulatory affairs, pre-clinical development, and quality assurance/compliance auditing. In that role oversaw 12 NDA submissions in Japan and achieved the first NDA approvals in Japan of etanercept (Enbrel®), Prevnar®, gemtuzumab ozogamicin (Mylotarg®), and levofolinate calcium (Isovorin®).
As Senior Vice President at Wyeth Vaccines, was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13® global BLA approvals; for the meningococcal B vaccine (Trumemba®) and the initial investigational Staphylococcus aureus vaccine clinical development programs.
Extensive clinical trial experience, having been responsible for the design, execution, and/or management of over 200 clinical trials, including 20 efficacy trials (including vaccines, Enbrel®, and Effexor®), involving over 150,000 patients at approximately 865 sites in 40 countries.
After leaving Pfizer in 2010, established Hudson Innovations, LLC, a pharmaceutical consulting, and licensing facilitation firm; and subsequently Equitas BioPharma Solutions, LLC, a firm that manages an alliance of independently owned and operated consulting firms providing services to the pharmaceutical industry.
He is the owner of an independent FINRA-registered investment advisory firm regulated by the State of New York (Aeolian Advisors Corp.), and is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) as co-head of Life Sciences Investment Banking.
Medical graduate from the University of Adelaide in South Australia, where he pursued postgraduate doctoral research in mucosal immunity and has an MBA from the Warwick Business School in the UK. He maintains medical registrations in the UK and Australia.
Dr. Kishor Wasan
R.PH., PH.D., FAAPS, FCAHS, FCSPS - CHIEF SCIENCE OFFICER AND RESEARCH ADVISOR
Dr. Wasan has received numerous awards (over 25) for his contributions to health sciences including the Canadian Society of Pharmaceutical Sciences Leadership award for outstanding contributions to Pharmaceutical Sciences in Canada and is a Fellow of the Canadian Academy of Health Sciences, the American Association of Pharmaceutical Scientists, and the Canadian Society of Pharmaceutical Sciences. Dr. Wasan has published over 550 peer-reviewed articles and abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. Most recently, Dr. Wasan served as the Dean and Professor (Retired) of the College of Pharmacy and Nutrition of the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan was associate dean of research and a tenured professor at the University of British Columbia until 2014. Dr. Wasan has extensive involvement in the development of new research and educational programs. He has demonstrated success in leading research initiatives through his many years of independent research at UBC. Wasan completed his undergraduate pharmacy education at the University of Texas at Austin, and a PhD in Cellular and Molecular Pharmacology from the University of Texas Medical Centre in Houston, Texas. Dr. Wasan has been a practicing pharmacist in both the retail and hospital settings and still maintains a pharmacist license from the State of Texas. Wasan was also a Distinguished University Scholar and Canadian Institutes of Health Research/iCo Therapeutics Inc. Research Chair in Drug Delivery for Neglected Global Diseases, continues to be a fellow of the Canadian Academy of Health Sciences, the American Association of Pharmaceutical Scientists, and the Canadian Society of Pharmaceutical Scientists. He is well-known in the post-secondary field for his strengths in research and education curriculum change. He was also the Co-Founder and current Co-Director of NGDI-UBC.
Chief Operations Officer
Renny has over 20 years of experience in the areas of corporate finance, legal and strategic business affairs. As CEO and Principal of Capex Ltd., Renny has completed extensive M&A projects across Western Canada, with a significant number of complex transactions. As a senior partner in Skymount Global, he assembled the Canadian Skymount Medical team and infrastructure.
Dr. Peter Hnik
MD, MHSc-Medical Officer and Clinical Trial Director
Since 1999, Dr. Hnik has designed and directed clinical trials in AMD and diabetic retinopathy. Since 2006, he has provided clinical guidance to multiple biotech and pharma companies, as well as financial institutions. He has authored numerous ocular publications and presentations at international forums. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences (NYAS). Dr. Hnik has served as a Clinical researcher and surgeon at the Eye Clinic of the Charles University Hospital where he was involved, among others, in treatment of glaucoma, ocular inflammation, diseases of retina and neuro-ophthalmology. He later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group.
BSP, ICD –Vice President of Operations
Christine is the owner of several pharmacies in Saskatchewan and currently sits as Chair of the Canadian Pharmacists Association. Christine also sits as Chair of the Board of Aither Ingredient Corporation. She is a board member of Pharmapod and is a board member of publicly traded company SEB. Christine also works with Women Entrepreneurs to help and mentor women in business.
Director of Operations
George is a Pharmacist and President of the Saskatchewan Pharmacy Association and Past President of the Saskatchewan College of Pharmacy. He has been a Business Operator for the last 28 years and Chair of Western Canada Shoppers Drug Mart Operators and Peers Group, Chair of the Economics Committee for the Saskatchewan Pharmacy Association, and Past Senator for the University of Regina.
Richard J.C. Grant
J.D.BA –Chief Legal Officer
Richard has over 35 years of legal, business and management experience in the energy and resources sectors worldwide. His experience has been gained at large international law firms, multi-national oil companies, a big four accounting firm and private and public junior energy companies.
Chief Marketing Officer
Zahra is a global marketing leader with extensive general and strategic marketing management experience, including multi-channel communications, customer experience, partnerships, and business development. She is known for successes in growing existing products and services, in addition to launching new ones. Zahra has over twenty-five years’ experience in marketing and communications, with a continuous record of achievements in publishing, financial services, and technology sectors. Recognized for leading cross-functional teams, both local and international, Zahra holds a Bachelor of Commerce degree from McGill University and an Advanced Management Course certificate from the McGill Executive Institute.
Senior Vice President – Business Development
Senior Adviser to US Government, Stephen is the Director of Partner Relations for the Global SOF Foundation. Prior to his position with the Foundation, Stephen served in the United States Navy for over 20 years as a Naval Aviator and Commanding Officer. He has a master’s from the Harvard School of Government, NPS and Purdue.
Strategic and Financial Advisor
Lee holds a Bachelor degree in International Business Management from the University of Victoria and is a Chartered Financial Analyst (CFA) Charterholder. He has over 20 years of experience as both an executive and investment banking professional focused on strategy, corporate planning, capital markets and business development. Lee is a proven dealmaker and value creator, having completed over $21 billion worth of merger and acquisition transactions, and over $11 billion in financing transactions. He possesses a deep understanding of the building blocks to grow a business, and he is assisting Skymount Medical in positioning and advancing its value creation opportunities and financing efforts.